Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Oral microbial biofilms: an update.

Mosaddad SA, Tahmasebi E, Yazdanian A, Rezvani MB, Seifalian A, Yazdanian M, Tebyanian H.

Eur J Clin Microbiol Infect Dis. 2019 Nov;38(11):2005-2019. doi: 10.1007/s10096-019-03641-9. Epub 2019 Aug 1. Review.

PMID:
31372904
2.

Needs assessment and research priorities in the oral and dental health with health promotion approach in Iran.

Rafie E, Karamali M, Bahadori M, Yazdanian M, Ravangard R.

J Educ Health Promot. 2019 May 14;8:93. doi: 10.4103/jehp.jehp_288_18. eCollection 2019.

3.

Lung tissue engineering: An update.

Tebyanian H, Karami A, Nourani MR, Motavallian E, Barkhordari A, Yazdanian M, Seifalian A.

J Cell Physiol. 2019 Nov;234(11):19256-19270. doi: 10.1002/jcp.28558. Epub 2019 Apr 10. Review.

PMID:
30972749
4.

The role of psychological theories in oral health interventions: A systematic review and meta-analysis.

Sanaei Nasab H, Yazdanian M, Mokhayeri Y, Latifi M, Niksadat N, Harooni J, Armoon B.

Int J Dent Hyg. 2019 May;17(2):142-152. doi: 10.1111/idh.12386. Epub 2019 Mar 6.

PMID:
30702796
5.

Cell Toxicity and inhibitory effects of Cyperus rotundus extract on Streptococcus mutans, Aggregatibacter actinomycetemcomitans and Candida albicans.

Khojaste M, Yazdanian M, Tahmasebi E, Shokri M, Houshmand B, Shahbazi R.

Eur J Transl Myol. 2018 Nov 30;28(4):7917. doi: 10.4081/ejtm.2018.7917. eCollection 2018 Nov 2.

6.

Anaphothrips sineconus and Hyalopterothrips brunneus, two new species of Anaphothrips genus-group (Thysanoptera) from Iran.

Alavi J, Yazdanian M, Minaei K.

Zootaxa. 2018 Mar 4;4388(3):437-443. doi: 10.11646/zootaxa.4388.3.10.

PMID:
29690448
7.

Commentary: Why Pharmaceutical Scientists in Early Drug Discovery Are Critical for Influencing the Design and Selection of Optimal Drug Candidates.

Landis MS, Bhattachar S, Yazdanian M, Morrison J.

AAPS PharmSciTech. 2018 Jan;19(1):1-10. doi: 10.1208/s12249-017-0849-3. Epub 2017 Jul 28.

PMID:
28755053
8.

Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System.

Bou-Chacra N, Melo KJC, Morales IAC, Stippler ES, Kesisoglou F, Yazdanian M, Löbenberg R.

AAPS J. 2017 Jul;19(4):989-1001. doi: 10.1208/s12248-017-0085-5. Epub 2017 May 17.

PMID:
28516359
9.

Lipophilicity in Drug Development: Too Much or Not Enough?

Bergström CAS, Yazdanian M.

AAPS J. 2016 Sep;18(5):1095-1100. doi: 10.1208/s12248-016-9947-5. Epub 2016 Jul 8.

PMID:
27393481
10.

The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers.

Parr A, Hidalgo IJ, Bode C, Brown W, Yazdanian M, Gonzalez MA, Sagawa K, Miller K, Jiang W, Stippler ES.

Pharm Res. 2016 Jan;33(1):167-76. doi: 10.1007/s11095-015-1773-4. Epub 2015 Aug 19.

11.

Role of dopamine D2-like receptors within the ventral tegmental area and nucleus accumbens in antinociception induced by lateral hypothalamus stimulation.

Moradi M, Yazdanian M, Haghparast A.

Behav Brain Res. 2015 Oct 1;292:508-14. doi: 10.1016/j.bbr.2015.07.007. Epub 2015 Jul 9.

PMID:
26166189
12.

Evaluation of cellular responses for a chimeric HBsAg-HCV core DNA vaccine in BALB/c mice.

Yazdanian M, Memarnejadian A, Mahdavi M, Motevalli F, Sadat SM, Vahabpour R, Khanahmad H, Soleimanjahi H, Budkowska A, Roohvand F.

Adv Biomed Res. 2015 Jan 6;4:13. doi: 10.4103/2277-9175.148296. eCollection 2015.

13.

Immunization of Mice by BCG Formulated HCV Core Protein Elicited Higher Th1-Oriented Responses Compared to Pluronic-F127 Copolymer.

Yazdanian M, Memarnejadian A, Mahdavi M, Sadat SM, Motevali F, Vahabpour R, Khanahmad H, Siadat SD, Aghasadeghi MR, Roohvand F.

Hepat Mon. 2013 Oct 23;13(10):e14178. doi: 10.5812/hepatmon.14178. eCollection 2013.

14.

Overview of determination of biopharmaceutical properties for development candidate selection.

Yazdanian M.

Curr Protoc Pharmacol. 2013 Mar;Chapter 9:Unit9.17. doi: 10.1002/0471141755.ph0917s60.

PMID:
23456615
15.

CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.

James J, Ruggeri B, Armstrong RC, Rowbottom MW, Jones-Bolin S, Gunawardane RN, Dobrzanski P, Gardner MF, Zhao H, Cramer MD, Hunter K, Nepomuceno RR, Cheng M, Gitnick D, Yazdanian M, Insko DE, Ator MA, Apuy JL, Faraoni R, Dorsey BD, Williams M, Bhagwat SS, Holladay MW.

Mol Cancer Ther. 2012 Apr;11(4):930-41. doi: 10.1158/1535-7163.MCT-11-0645. Epub 2012 Feb 7.

16.

2,7-Disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formation.

Wells-Knecht KJ, Ott GR, Cheng M, Wells GJ, Breslin HJ, Gingrich DE, Weinberg L, Mesaros EF, Huang Z, Yazdanian M, Ator MA, Aimone LD, Zeigler K, Dorsey BD.

Chem Res Toxicol. 2011 Nov 21;24(11):1994-2003. doi: 10.1021/tx200304r. Epub 2011 Nov 4.

PMID:
22023349
17.

Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.

Hudkins RL, Raddatz R, Tao M, Mathiasen JR, Aimone LD, Becknell NC, Prouty CP, Knutsen LJ, Yazdanian M, Moachon G, Ator MA, Mallamo JP, Marino MJ, Bacon ER, Williams M.

J Med Chem. 2011 Jul 14;54(13):4781-92. doi: 10.1021/jm200401v. Epub 2011 Jun 2.

PMID:
21634396
18.

A comprehensive study demonstrating that p-glycoprotein function is directly affected by changes in pH: implications for intestinal pH and effects on drug absorption.

Mitra P, Audus K, Williams G, Yazdanian M, Galinis D.

J Pharm Sci. 2011 Oct;100(10):4258-68. doi: 10.1002/jps.22596. Epub 2011 Apr 27.

PMID:
21538355
19.

Is PAMPA a useful tool for discovery?

Galinis-Luciani D, Nguyen L, Yazdanian M.

J Pharm Sci. 2007 Nov;96(11):2886-92.

PMID:
17694546
20.

George Zografi: researcher and educator.

Bummer PM, Yazdanian M.

Pharm Res. 2006 Oct;23(10):2235-8. Epub 2006 Sep 7. No abstract available.

PMID:
16957836
21.

Tetrazole compounds: the effect of structure and pH on Caco-2 cell permeability.

Young AM, Audus KL, Proudfoot J, Yazdanian M.

J Pharm Sci. 2006 Apr;95(4):717-25.

PMID:
16498570
22.
23.

A structure-permeability study of small drug-like molecules.

Fichert T, Yazdanian M, Proudfoot JR.

Bioorg Med Chem Lett. 2003 Feb 24;13(4):719-22.

PMID:
12639566
24.

Permeability measurement of macromolecules and assessment of mucosal antigen sampling using in vitro converted M cells.

Liang E, Kabcenell AK, Coleman JR, Robson J, Ruffles R, Yazdanian M.

J Pharmacol Toxicol Methods. 2001 Sep-Oct;46(2):93-101.

PMID:
12481846
25.

Contribution of efflux pump activity to the delivery of pulmonary therapeutics.

Hamilton KO, Yazdanian MA, Audus KL.

Curr Drug Metab. 2002 Feb;3(1):1-12. Review.

PMID:
11876574
26.

Modulation of P-glycoprotein activity in Calu-3 cells using steroids and beta-ligands.

Hamilton KO, Yazdanian MA, Audus KL.

Int J Pharm. 2001 Oct 9;228(1-2):171-9.

PMID:
11576779
27.

Multidrug resistance-associated protein-1 functional activity in Calu-3 cells.

Hamilton KO, Topp E, Makagiansar I, Siahaan T, Yazdanian M, Audus KL.

J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.

PMID:
11504821
28.

Nonpeptidic, monocharged, cell permeable ligands for the p56lck SH2 domain.

Proudfoot JR, Betageri R, Cardozo M, Gilmore TA, Glynn S, Hickey ER, Jakes S, Kabcenell A, Kirrane TM, Tibolla AK, Lukas S, Patel UR, Sharma R, Yazdanian M, Moss N, Beaulieu PL, Cameron DR, Ferland JM, Gauthier J, Gillard J, Gorys V, Poirier M, Rancourt J, Wernic D, Llinas-Brunet M.

J Med Chem. 2001 Jul 19;44(15):2421-31.

PMID:
11448224
29.

P-glycoprotein efflux pump expression and activity in Calu-3 cells.

Hamilton KO, Backstrom G, Yazdanian MA, Audus KL.

J Pharm Sci. 2001 May;90(5):647-58.

PMID:
11288109
30.

Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium.

Foster KA, Yazdanian M, Audus KL.

J Pharm Pharmacol. 2001 Jan;53(1):57-66.

PMID:
11206193
31.
32.

Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery.

Foster KA, Avery ML, Yazdanian M, Audus KL.

Int J Pharm. 2000 Nov 4;208(1-2):1-11.

PMID:
11064206
33.

Evaluation of an accelerated Caco-2 cell permeability model.

Liang E, Chessic K, Yazdanian M.

J Pharm Sci. 2000 Mar;89(3):336-45.

PMID:
10707014
34.

Blood-brain barrier properties of human immunodeficiency virus antiretrovirals.

Yazdanian M.

J Pharm Sci. 1999 Oct;88(10):950-4. Review. No abstract available.

PMID:
10514337
35.

Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds.

Yazdanian M, Glynn SL, Wright JL, Hawi A.

Pharm Res. 1998 Sep;15(9):1490-4. No abstract available.

PMID:
9755906
36.

Note: sucrose transport and metabolism in Clostridium beijerinckii NCIMB 8052.

Tangney M, Rousse C, Yazdanian M, Mitchell WJ.

J Appl Microbiol. 1998 May;84(5):914-9.

37.
39.

Supplemental Content

Loading ...
Support Center